ASCO 2021: Nivolumab Plus Cabozantinib Outperforms Sunitinib in Advanced Renal Cell Carcinoma Regardless of Baseline Disease Characteristics
Outcomes of CheckMate 9ER were evaluated by risk status, pattern of metastasis, and disease burden
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.